Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.

Vordos D, Paule B, Vacherot F, Allory Y, Salomon L, Hoznek A, Yiou R, Chopin D, Abbou CC, de la Taille A.

BJU Int. 2004 Sep;94(4):524-7.

3.

[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].

Rexer H.

Urologe A. 2011 Jun;50(6):722-4. doi: 10.1007/s00120-011-2579-6. German. No abstract available.

PMID:
21584827
4.

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.

Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL.

J Clin Oncol. 2010 Apr 20;28(12):2070-6. doi: 10.1200/JCO.2009.25.4524. Epub 2010 Mar 22.

5.

Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.

Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, Dimopoulos MA, Bamias A.

Urology. 2005 Jan;65(1):126-30.

PMID:
15667877
6.

Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).

Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R.

Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6.

7.

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

Hussain M, Tangen CM, Lara PN Jr, Vaishampayan UN, Petrylak DP, Colevas AD, Sakr WA, Crawford ED; Southwest Oncology Group.

J Clin Oncol. 2005 Dec 1;23(34):8724-9.

8.

Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.

Perry CJ, Sundar S.

Clin Genitourin Cancer. 2012 Sep;10(3):207-9. doi: 10.1016/j.clgc.2012.01.011. Epub 2012 Mar 23. No abstract available.

PMID:
22445962
9.

Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.

Sella A, Sternberg C, Kovel S, Yarom N, Skoneczna I.

BJU Int. 2007 Sep;100(3):533-5. Epub 2007 Jun 8.

10.

An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.

Salzberg M, Rochlitz C, Morant R, Thalmann G, Pedrazzini A, Roggero E, Schönenberger A, Knuth A, Borner M.

Onkologie. 2007 Jul;30(7):355-60. Epub 2007 Jun 27.

PMID:
17596743
11.

Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.

Miura N, Numata K, Kusuhara Y, Shirato A, Hashine K, Sumiyoshi Y.

Jpn J Clin Oncol. 2010 Nov;40(11):1092-8. doi: 10.1093/jjco/hyq100. Epub 2010 Jun 29.

12.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
13.
14.

Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.

Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, Akaza H.

Jpn J Clin Oncol. 2008 May;38(5):365-72. doi: 10.1093/jjco/hyn029. Epub 2008 Apr 15.

15.

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.

Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ.

J Clin Oncol. 1999 Jun;17(6):1664-71.

PMID:
10561202
16.

Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.

Meng LJ, Wang J, Fan WF, Pu XL, Liu FY, Yang M.

J Cancer Res Clin Oncol. 2012 Feb;138(2):333-9. doi: 10.1007/s00432-011-1101-2. Epub 2011 Dec 2.

PMID:
22134838
17.

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.

Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD.

J Clin Oncol. 2004 Jul 1;22(13):2532-9.

18.

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.

Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, D'Hondt L, Dopchie C, Verschaeve V, Duck L, Verhoeven D, Jousten P, Bonny MA, Moxhon AM, Tombal B, Kerger J.

J Clin Oncol. 2008 Nov 10;26(32):5261-8. doi: 10.1200/JCO.2008.16.9524. Epub 2008 Sep 15.

19.

Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial.

Uemura H, Yanagisawa M, Ikeda I, Fujinami K, Iwasaki A, Noguchi S, Noguchi K, Kubota Y; Yokohama Bone Metastasis Study Group.

Int J Clin Oncol. 2013 Jun;18(3):472-7. doi: 10.1007/s10147-012-0406-8. Epub 2012 Apr 11.

PMID:
22491982
20.

[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].

Miura N, Numata K, Azuma K, Hashine K, Sumiyoshi Y.

Gan To Kagaku Ryoho. 2006 Jun;33(6):841-4. Japanese.

PMID:
16770110
Items per page

Supplemental Content

Write to the Help Desk